| Project/Area Number |
15K11286
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Surgical dentistry
|
|---|
| Research Institution | Tsurumi Junior College |
|---|
Principal Investigator |
Fujihara Hisako 鶴見大学短期大学部, 歯科衛生科, 准教授 (80396746)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
川口 浩司 鶴見大学, 歯学部, 准教授 (50277951)
宮嶋 千秋 鶴見大学, 歯学部, 学部助手 (50723722)
馬杉 亮彦 鶴見大学, 歯学部, 助教 (80351922)
山田 浩之 岩手医科大学, 歯学部, 教授 (90267542)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | 口腔がん / 転移 / 浸潤 / 分子標的治療薬 / 分子標的薬 / 浸潤能 / 転移能 |
|---|
| Outline of Final Research Achievements |
In this report, mechanism of oral cancer invasion and metastasis was analyzed using PARP inhibitor which is one of molecular target drugs and currently under clinical trial for breast cancer. Materials used in this reports are three kinds of oral cancer derived cells, Ca9-22, SAS, and HSC-2 and Olaparib (AZD2281) as PARP inhibitor.
In the first year, PARP inhibitor showed significant decrease of 1) cell proliferation, 2) cell migration, 3) cell infiltration, and 4) cell adhesion except cell (Ca9-22) adhesion for laminin coating, which showed significant increase of cell adhesion using with Olaparib. Next, xenografted tumors were generated by injection of tumor cells into masseter muscles. Tumor volumes of control group mice increased during the experimental period. However, tumor growth rate of AZD2281 group significantly decreased compared to the control group after tumor cell injection. Xenografted tumor invasion to mandibule was also compared between Olaparib/control groups.
|
